Berberine in Inflammatory Bowel Disease: Integrative Regulation of the Microbiota–Immune–Barrier Axis
International Journal of Molecular Sciences · 09.06.2026 · 27 (12) · 5220
DOI: 10.3390/ijms27125220 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift International Journal of Molecular Sciences, online erschienen am 09.06.2026. Verfasst von Junling Tang und 7 weiteren Autor:innen. Beteiligte Einrichtung: School of Clinical Medicine, Chengdu University of Traditional Chinese Medicine, Chengdu 610072, China. Hauptthemen laut MEDLINE: Berberine, Inflammatory Bowel Diseases, Gastrointestinal Microbiome. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 152 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: the Special Project of Scientific and Technological Research of the Sichuan Provincial Administration of Traditional Chinese Medicine, the Key Research and Development Project of the Sichuan Provincial Department of Science and Technology, The National Natural Science Foundation of China.
Abstract (Originalsprache)
Inflammatory bowel disease (IBD) is a chronic relapsing disorder associated with dysregulated interactions among the gut microbiota, mucosal immunity, and the intestinal barrier. Although current treatments have improved disease control, incomplete response, adverse effects, and relapse remain common. Berberine, a natural isoquinoline alkaloid, has gained attention as a multitarget compound with potential relevance to IBD. This narrative review summarizes evidence published up to March 2026 on the pharmacological basis, delivery optimization, clinical translation, and microbiota–immune–barrier axis regulation of berberine in IBD. Current evidence suggests that berberine may reshape gut microbial communities, regulate mucosal immune responses, and support epithelial barrier repair, thereby contributing to the restoration of intestinal homeostasis. Emerging formulation strategies, particularly microbiota-responsive and intestine-targeted delivery systems, may improve local exposure and strengthen its therapeutic potential. However, the current evidence is still dominated by preclinical studies. Clinical data remain limited, and the causal links among microbial remodeling, immune modulation, and barrier restoration are not yet fully defined. Future work should prioritize mechanistic validation, clinically relevant delivery design, and well-controlled clinical trials to clarify the role of berberine in personalized IBD management.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- School of Clinical Medicine, Chengdu University of Traditional Chinese Medicine, Chengdu 610072, China.
- Hospital of Chengdu University of Traditional Chinese Medicine, Chengdu 610072, China.
ORCID-Profile: Junling Tang, Siyu Chen
Förderung
- the Special Project of Scientific and Technological Research of the Sichuan Provincial Administration of Traditional Chinese Medicine
- the Key Research and Development Project of the Sichuan Provincial Department of Science and Technology
- The National Natural Science Foundation of China
Zitieren
APA
Tang, J., Wang, C., Yang, Y., Cheng, X., Chen, S., Zhou, S., Ma, J., & Feng, P. (2026). Berberine in Inflammatory Bowel Disease: Integrative Regulation of the Microbiota–Immune–Barrier Axis. International Journal of Molecular Sciences, 27(12), 5220. https://doi.org/10.3390/ijms27125220
Vancouver
Tang J, Wang C, Yang Y, Cheng X, Chen S, Zhou S, et al. Berberine in Inflammatory Bowel Disease: Integrative Regulation of the Microbiota–Immune–Barrier Axis. International Journal of Molecular Sciences. 2026;27(12):5220. doi:10.3390/ijms27125220
BibTeX
@article{Tang2026,
author = {Tang, Junling and Wang, Chuanhua and Yang, Yang and Cheng, Xiangxiong and Chen, Siyu and Zhou, Shiwen and Ma, Jing and Feng, Peimin},
title = {Berberine in Inflammatory Bowel Disease: Integrative Regulation of the Microbiota–Immune–Barrier Axis},
journal = {International Journal of Molecular Sciences},
year = {2026},
volume = {27},
number = {12},
pages = {5220},
doi = {10.3390/ijms27125220}
}
EUVIMED